In an effort to address the global health threat of antimicrobial resistance (AMR), Innovate UK, LifeArc, and Medicines Discovery Catapult have jointly launched the PACE (Pathways to Antimicrobial Clinical Efficacy) initiative. With £30m (around €34,5m) in funding, PACE aims to support early-stage innovations aimed at countering AMR.
The UK is making €15m investment in its biopharmaceutical manufacturing industry via its national innovation agency Innovate UK. It is part of the country’s larger push to support the domestic Life Sciences.
British researchers have proven that a new gene can prevent progression of hereditary kidney damage in mice.
UK-based CRO Cresset has expanded its senior leadership team with the appointment of Nick Foster as Vice President of their Discovery CRO business.
Dr Mark Chadwick will bring extensive industry knowledge to his new role as Strategic Business Advisor at UK-based Ingenza Ltd.
At the beginning of november, OxSonics Therapeutics has appointed Jérôme Marzinski as its Chief Executive Officer.
Lee Patterson joins UK-based Charnwood Molecular as new CEO. After nearly 25 years at UK-based Charnwood Molecular, Prof. Steve Allin has stepping down as CEO. He will remain as an investor and Board advisor.
Since the beginning of March, Dr Neil Torbett has been the new Chief Executive Officer of Cambridge-based PhoreMost Ltd.